Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

Fig. 4

Combination treatment with RAM2061 and PI leads to induction of the ICD pathway markers. MM cells were incubated with RAM2061 (50 or 100 nM) for 48 h with or without sequential (added after 24 h, denoted by *) or concurrent PI treatment (Bor: 3 nM (MM.1S), 5 nM (JJN3 and RPMI-8226), 15 nM (ALMC-2), Carf: 20 nM). a Immunoblot analysis of secreted HMGB1 was performed using media collected from cells. b, c Cell surface levels of calreticulin were measured by flow cytometry. Data are expressed as the average percentage of calreticulin positive (n = 3, data are displayed as mean ± stdev, * denotes p < 0.05. ** denotes p < 0.01. *** denotes p < 0.001 per t-test). Blots are representative of three independent experiments

Back to article page